LungLifeAI Logo

LungLife AI Clinical Laboratory achieves CAP accreditation

November 22, 2021

19 November 2021

LungLife AI, Inc.
(the “Company” or “LungLife”)

 

LungLife AI Clinical Laboratory achieves CAP accreditation

Independent inspection confirms highest standard of care for laboratory patients

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that its clinical laboratory in Thousand Oaks, California has been awarded accreditation by the College of American Pathologists (CAP). The Company, whose clinical laboratory is already CLIA certified, voluntarily sought the accreditation as part of its on-going commitment to maintaining best in class quality systems.

 

The Company’s laboratory processes have been independently assessed by the CAP, the world’s largest organisation of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programmes, during a recent on-site inspection designed to ensure the highest standard of care for all laboratory patients.

 

As part of this process, the inspectors examine a laboratory’s records and quality control procedures, as well as laboratory staff qualifications, equipment, facilities, safety programme and overall management. The U.S. federal government recognises the CAP Laboratory Accreditation Program as being equal-to or more-stringent than the government’s own inspection programme, and the Centers for Medicare and Medicaid Services (CMS) have granted the CAP Laboratory Accreditation Program “deeming authority,” which allows for CAP accreditation in lieu of a CMS inspection.

 

Lara Baden, VP Clinical Operations, LungLife AI, commented: “We are proud of the recognition of our quality by the College of American Pathologists through receiving this accreditation, which reflects our commitment to maintaining the highest standards of excellence in laboratory testing for patients and ensuring that our work practices meet the rigorous CAP assessment standards. This accreditation will provide ordering physicians and patients a further degree of confidence in the results they are receiving for our LungLB® test as well as for future products.”

For the full announcement, please click here. 

 

Recent News

Notice of Results
Holding(s) in Company
Holding(s) in Company

Subscribe for Email Alerts

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
chevron-down